Abiomed | Sustainability Performance
Abiomed, Inc. develops medical devices focused on heart support and recovery, offering technologies that assist in cardiovascular treatment.
1981
United States
1,001 - 5,000 employees
Medical Device
$1B - 10B in revenue
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#7395
Overallⓘ#1629
in United Statesⓘ#121
in Medical DeviceⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Abiomed Inc (acquired by Johnson & Johnson 2022 USD 16.6 billion), US medical devices (Impella heart pump major), has faced sustained class actions over the contested 2022 USD 16.6 billion J&J acquisition integration challenges affecting US institutional shareholders, plus periodic US FDA enforcement scrutiny over alleged inadequate Impella heart pump product safety practices affecting US institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.